"DHE plays a unique clinical role in the acute treatment of migraine, providing patients long-lasting effects and the unique ...

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...

A budget proposal from President Donald Trump’s administration would cut a federal grant that provides $56 million annually ...

A drug derived from ketamine will be added to the PBS, helping tens of thousands of Australians struggling with depression to ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who ...

Naloxone, which can reverse overdoses of opioids, has been available in the U.S. without a prescription since March of 2023, ...

Kindeva Drug Delivery, located off of Newtown Pike and Citation Boulevard, specializes in manufacturing life-saving ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.